Health News Releases

  • Today September 30
February 23, 10:35
Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)
Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron announce the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to
February 22, 11:50
Medidata Bolsters Senior Leadership Team to Further Accelerate the Digital Transformation of Life Sciences with Unmatched End-to-End Solutions
Medidata, a Dassault Systèmes company, today announced a new leadership structure designed to fuel its mission of creating end-to-end solutions that power smarter treatments and healthier people. The
February 22, 10:40
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy
Masimo (NASDAQ: MASI) today announced the findings of a prospective, double-blinded, randomized controlled study published in Medicine in which Dr. Jin Hee Ahn and colleagues at the Sungkyunkwan Unive
February 22, 10:10
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.
February 19, 10:59
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and
February 14, 08:55
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. These ana
February 10, 11:00
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), a
February 09, 10:30
Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial, which announces the US lau
February 08, 15:35
Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise
Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise
February 08, 15:10
Parse Biosciences Announces Evercode TCR and Gene Capture
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Pa
February 08, 10:30
KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya
The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in
February 08, 10:00
IDC MarketScape Names Medidata a Leader in Life Science R&D Risk-Based Monitoring Solutions Vendor Assessment
Medidata, a Dassault Systèmes company, announced it has been positioned as a Leader in the IDC MarketScape “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment (doc #US48
February 06, 10:20
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022). Takeda chief financial officer, Costa Saroukos, commented:
February 05, 11:20
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanade
February 05, 10:55
Dentalis Animal Health appoints Advisory Board
Dentalis Animal Health, a company specializing in Oral Health care for companion animals, has announced the appointment of its Advisory Board. Michael Kelly Michael Kelly is an Animal Health Pha
February 05, 09:40
Dexlevo’s GOURI Symposium and Brand Event at IMCAS 2023
Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris. IMCAS (International
January 30, 17:30
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular
January 27, 11:40
Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifes
January 26, 16:26
Galderma Announces the Launch of FACE by Galderma™ - a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction
Galderma has announced the launch of FACE by Galderma™, an innovative augmented reality application. The ground-breaking solution enables aesthetic practitioners and patients to visualize treatment re
January 26, 10:40
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed Gmb
January 25, 15:35
AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics ma
January 24, 11:15
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for
January 24, 10:13
Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery
Masimo (NASDAQ: MASI) today announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Moha
January 21, 13:20
IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio
Galderma will be showcasing the latest updates from across its portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris from January 26-28, 2023. Events will
January 20, 14:10
Chief Rabbi of Israel Affirms Aleph Farms’ Cultivated Steak is Kosher
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that Israeli Chief Rabbi, David Baruch Lau, has ruled its cultivate
January 20, 11:26
Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: L
January 19, 14:30
TA Announces Strategic Growth Investment in Synokem Pharmaceuticals
TA Associates (“TA”), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (“Synokem” or “the Company”). Syn
January 19, 09:45
Agenda 2023: PQE Group Boosting Growth by Reinforcing Service Portfolio and Entering New Markets
It has been another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) with 32 offices worldwide. Recently named “Best Managed Company” by Deloitt
January 18, 10:10
Takeda Named Global Top Employer for Sixth Consecutive Year
Takeda (TSE:4502/NYSE:TAK) today announced that, for the sixth consecutive year, it was one of only 15 companies to achieve global Top Employer® certification for 2023. In addition to the global certi
January 18, 09:25
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination of trifluridine/tipiracil (LONSURF®) and bevacizumab in a
January 18, 09:20
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
The Top Employers Institute awarded Boehringer Ingelheim for the third year in succession a “Global Top Employer”, one of the world’s 15 best employers. The certification also highlights the company’s
January 17, 10:15
JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairma
January 13, 14:40
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with loca
January 12, 09:00
Global talent leader WilsonHCG acquires Personify to further expand its healthcare and life sciences talent solutions
WilsonHCG, a global talent leader, has announced the acquisition of Personify, an award-winning recruitment process outsourcing (RPO) provider. Personify specializes in the life sciences, healthcare,
January 11, 10:10
Limb Lengthening Expert Dr. Dror Paley Opens First Clinic in Middle East at UAE’s Burjeel Medical City
As part of its ongoing efforts to focus on complex care and pediatric sub-specialties, Burjeel Holdings, one of the leading private healthcare services providers in the MENA region, in collaboration w
January 10, 13:30
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud Univ
January 10, 09:55
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address hi
January 10, 09:40
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for
January 09, 13:30
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
Masimo (NASDAQ: MASI) today announced the findings of a before-and-after study published in PLoS ONE in which Dr. Ahmed Balshi and colleagues at King Saud Medical City in Riyadh, Saudi Arabia, evaluat
January 06, 14:40
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being stu
January 04, 11:43
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMi
January 04, 10:40
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluat
December 30, 2022 13:35
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMic
December 23, 2022 09:25
Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover no
December 21, 2022 09:45
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the
December 20, 2022 10:05
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).
December 19, 2022 11:35
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an
December 16, 2022 16:00
CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid dis
December 16, 2022 11:25
Artilysin®: Fearless Into the Post-antibiotic Era
The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial prote
December 14, 2022 16:45
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for
25 per page50 per page75 per page100 per page